



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

PTT2.0

Treatment of childhood tumours has become increasingly successful in the recent decades. With new treatment methods, about 75%-80% of children and juveniles that are diagnosed with a tumour for the first time can be cured. On the other hand, only about 20% of children and juveniles that have a relapse of brain tumours or sarcomas can be cured again. The PTT 2.0 project runs parallel to INFORM. This means that PTT2.0 is designed to include patients with a recurrent or progressive brain tumour, sarcoma or tumours of the nervous system that cannot be included to INFORM. The Universitätsklinikum Heidelberg in Germany is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

Similarly to INFORM, researchers look for mutations in a patients DNA and try to identify possible targeted therapies. Targeted therapies are medicines that attack the property of the tumour caused by a mutation. This is a new approach and researchers hope to be able to better treat tumours with them. The applied identification techniques use archival material only, and are similar to the techniques used in INFORM. This allows for the inclusion of patients even when no fresh tumour sample is available, which is often the case in brain tumours. PTT2.0 is also interested in determining, whether the information provided to doctors helped make decisions on the kind of therapy used. The PTT2.0 project is currently in preparation in Switzerland.

Contact details for the sponsor representative in Switzerland:

Partner Relations
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89